NR3C1 and Cowden syndrome 1: The glucocorticoid receptor antagonist mifepristone may be considered a potential option for CS treatment during a COVID-19 pandemic, since an improvement in CS metabolic comorbidities has been observed in up to 75% of patients [67, 82].